Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 vs QMF149 in inadequately controlled asthma
CTR20170626Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma, sponsored by Novartis. Started Jul 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20170626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170626.